NGEN

NervGen Pharma Corp

1.59

Oct 16 • 3:59 PM ET -0.03 (-1.85%)

1.56

Aftermarket • 7:57 PM ET -0.03 (-1.89%)

Healthcare Biotechnology Canada Micro NASD

Peers: ACIU AVXL VYGR DTIL PRLD TARA EDIT ARTV PALI RZLT

| Held by: GWX IBRN

Scroll to Statements

Index	-
Market Cap	170.96M
Enterprise Value	109.79M
Income	-44.64M
Sales	0.00M
Book/sh	0.11
Cash/sh	0.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Apr 03, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	13.89
P/C	2.79
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.23
Current Ratio	1.23
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.54
EPS next Y	-0.40
EPS next Q	-0.09
EPS this Y	1.18%
EPS next Y	7.64%
EPS next 5Y	5.80%
EPS past 3/5Y	-13.03% -10.94%
Sales past 3/5Y	- -
EPS Y/Y TTM	-96.62%
Sales Y/Y TTM	-
EPS Q/Q	-149.78%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-337.95% -

Insider Own	16.68%
Insider Trans	0.00%
Inst Own	11.22%
Inst Trans	12.58%
ROA	-117.52%
ROE	-776.07%
ROIC	-366.59%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-12.01%
SMA50	-18.18%
SMA200	-47.96%
Trades

Shs Outstand	106.41M
Shs Float	89.59M
Short Float	6.51%
Short Ratio	11.00
Short Interest	5.83M
52W High	6.30 -74.76%
52W Low	1.55 2.58%
Volatility	6.85% 6.45%
ATR (14)	0.11
RSI (14)	32.53
Beta	0.73
Rel Volume	0.73
Avg Volume	530.06K
Volume	388,391

Perf Week	-8.09%
Perf Month	-29.96%
Perf Quarter	-8.09%
Perf Half Y	-60.93%
Perf YTD	-71.61%
Perf Year	-47.00%
Perf 3Y	23.69%
Perf 5Y	-15.87%
Perf 10Y	-
Recom	1.00
Target Price	12.50
Prev Close	1.62
Price	1.59
Change %	-1.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-13-26	Initiated	Leerink Partners	Outperform	$10
Jun-11-26	Initiated	TD Cowen	Buy
Apr-27-26	Initiated	H.C. Wainwright	Buy	$18

Oct-12-26 07:15AM	NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury (GlobeNewswire)
Sep-25-26 04:30PM	NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments (GlobeNewswire)
Sep-09-26 07:30AM	NervGen to Host Inaugural R&D Day on September 30, 2026 (GlobeNewswire)
Aug-13-26 07:30AM	NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
May-26-26 07:15AM	NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study (GlobeNewswire)
11:27PM	Loading…
May-21-26 11:27PM	NervGen Announces Pricing of US$60.0 Million Public Offering of Securities (GlobeNewswire) -43.48%
04:01PM	NervGen Announces Proposed Public Offering of Securities (GlobeNewswire)
May-18-26 07:15AM	NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-27-26 07:30AM	NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer (GlobeNewswire)
Apr-13-26 07:45AM	NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Apr-07-26 07:30AM	NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia (GlobeNewswire) -9.57%
Mar-31-26 07:45AM	NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-12-26 04:15PM	NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange (GlobeNewswire) -6.98%
Mar-04-26 07:30AM	NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs (GlobeNewswire) +8.10%
Feb-18-26 07:30AM	NervGen Pharma to Participate at Upcoming Investor Conferences (GlobeNewswire)
04:15PM	Loading…
Feb-12-26 04:15PM	NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams (GlobeNewswire)
Feb-11-26 07:00AM	NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium (GlobeNewswire)
Feb-09-26 07:00AM	NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury (GlobeNewswire)
Jan-20-26 07:00AM	NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing (GlobeNewswire) -6.93%
Jan-08-26 06:30AM	NervGen Pharma Begins Trading on Nasdaq Today (GlobeNewswire)

NervGen Pharma Corp. operates as a clinical stage biotech company. It engages in the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. The company was founded by Harold Punnett and William Joseph Radvak on January 19, 2017 and is headquartered in Vancouver, Canada.

PresidentDr. Adam H. Rogers M.D.

Co-Founder & Independent DirectorDr. Harold Martin Punnett D.M.D.

Chief Medical Advisor & DirectorDr. Randall E. Kaye M.D.

M.D.Dr. Keith A. Vendola M.B.A.

Senior Vice President of Technical OperationsDr. Charles V. Olson D.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NGEN

NervGen Pharma Corp

Upgrade your Finviz experience